Physician profile
Dan Vardi
NPI 1245302108
$3,114.52
in general payments reported to CMS, 2019-2025
31 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $194 · 2021: $375 · 2022: $420 · 2023: $520 · 2024: $418 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $652.82 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.87 | 2019-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals Lp | $298.26 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Genzyme Corporation | $176.14 | 2020-2025 | |
| Mylan Specialty L.P. | $171.07 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $153.87 | 2019-2021 | |
| Grifols USA, LLC | $141.50 | 2019-2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $134.35 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $113.16 | 2019-2022 | |
| Csl Behring | $95.36 | 2020-2025 | Kcentra |
| Regeneron Healthcare Solutions, INC. | $93.30 | 2023-2025 | Dupixent |
| Viatris Specialty LLC | $89.78 | 2025 | Yupelri |
| Insmed, INC. | $73.23 | 2023-2025 | Arikayce, Brinsupri |
| Fisher & Paykel Healthcare INC | $60.29 | 2019 | |
| United Therapeutics Corporation | $49.08 | 2025 | Tyvaso |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $38.84 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $33.12 | 2023-2025 | Tezspire |
| Pulmonx Corporation | $32.63 | 2019-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Merck Sharp & Dohme LLC | $32.14 | 2019-2025 | Zerbaxa |
| Resmed Corp | $29.65 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.25 | 2023 | Glassia |
| Alnylam Pharmaceuticals INC. | $21.45 | 2023 | Givlaari |
| Ambu INC. | $19.88 | 2023 | |
| Pfizer INC. | $19.44 | 2019 | |
| Philips North America LLC | $17.42 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.47 | 2022 | |
| 3b Medical, INC. | $16.02 | 2024 | Luna |
| Chiesi USA, INC. | $14.85 | 2024 | Cleviprex |
| Abbvie INC. | $14.14 | 2021 | |
| Genentech USA, INC. | $11.75 | 2019 | |
| Allergan, INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Vardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.